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Objectives We examined the relationship between body mass index (BMI), waist circumference, and incident HF in men
with and without pre-existing coronary heart disease (CHD) and assessed the contribution of plasma leptin con-
centration to these associations.
Background Leptin has been proposed as a potential link between obesity and heart failure (HF).
Methods This was a prospective study of 4,080 men age 60 to 79 years with no diagnosed HF followed for a mean period
of 9 years, in whom there were 228 incident HF cases.
Results Increased BMI was associated with significantly increased risk of HF in men with and without pre-existing CHD
(myocardial infarction or angina) after adjustment for cardiovascular risk factors including C-reactive protein. The
adjusted hazard ratios (HRs) associated with a 1-SD increase in BMI were 1.37 (95% confidence interval [CI]:
1.09 to 1.72) and 1.18 (95% CI: 1.00 to 1.39) in men with and without CHD, respectively. Increased leptin was
significantly associated with an increased risk of HF in men without pre-existing CHD, independent of BMI and
potential mediators (adjusted HR for a 1-SD increase in log leptin: 1.30 [95% CI: 1.06 to 1.61]; p  0.01). How-
ever, no association was seen in those with pre-existing CHD (corresponding HR: 1.06 [95% CI: 0.77 to 1.45];
p  0.72). Adjustment for leptin abolished the association between BMI and HF in men with no CHD; in those
with CHD, the association between BMI and HF remained significant (p  0.03). Similar patterns were seen for
waist circumference.
Conclusions In the absence of established CHD, the association between obesity and HF may be mediated by plasma leptin.
In those with CHD, obesity appears to increase the risk of HF independent of leptin. (J Am Coll Cardiol 2011;
58:1870–7) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.057Heart failure (HF) is a major cause of morbidity and
mortality, especially in older people (1). With an increas-
ingly aging population, prevention of HF in the elderly is a
growing public health concern. It is becoming recognized
that obesity is a major risk factor for the development of
HF, and this has been reported in the general population
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accepted June 21, 2011.(2–8), in the elderly population (9–12), and in patients with
established coronary heart disease (CHD) (13,14). How-
ever, the mechanisms by which obesity increases the risk of
HF remain uncertain. In most studies, the association
between obesity and HF has been shown to be independent
of the established risk factors for HF including hypertension
See page 1878
and diabetes (2–14). Potential mechanisms have been pro-
posed in the pathogenesis of obesity-related HF including
inflammation and abnormalities in adipokine pathways
(15,16). Adipose tissue is known to secrete leptin, a circu-
lating peptide hormone produced by adipocytes that regu-
lates body weight by effects on food intake and metabolism
(17). Plasma leptin levels increase with body mass index
(BMI) and particularly with an increasing percentage of
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October 25, 2011:1870–7 Obesity, Leptin, and Heart Failurebody fat (18). Leptin is usually increased in patients with
HF (19). Evidence from clinical and experimental studies
have suggested that leptin regulates alterations in myocar-
dial metabolism, promotes cardiomyocyte hypertrophy, and
may influence cardiac remodeling (including changes in cell
death and fibrosis) (17,20,21). This has led to the sugges-
tion that plasma leptin may be the mechanism linking
obesity and HF (17,18), although the association between
leptin and HF in prospective studies has not been clearly
established (22). Few prospective studies have investigated
the role of leptin in mediating the relationship between
obesity and HF in older adults, although in a study of adults
with established CHD, leptin did not mediate the associa-
tion between obesity and HF (13). We examined the
relationship between leptin and obesity and the risk of
incident HF in older men with and without established
CHD who were free of HF at baseline. We hypothesized
that plasma leptin provides the link between obesity and risk
of HF in older men without CHD.
Subjects and Methods
The British Regional Heart Study is a prospective study of
cardiovascular disease involving 7,735 men age 40 to 59
years drawn from 1 general practice in each of 24 British
towns who were screened between 1978 and 1980 (23). The
population studied was socioeconomically representative of
British men and consisted almost entirely of white Europe-
ans (99%). From 1998 to 2000, all surviving men, now
aged 60 to 79 years, were invited for a 20-year follow-up
examination. All men completed a mailed questionnaire
providing information on their lifestyle and medical history,
had a physical examination, and provided a fasting blood
sample collected using the Sarstedt Monovette system. The
samples were frozen and stored at 20°C on the day of
collection and transferred in batches for storage at 70°C
until analysis, performed after no more than 1 freeze-thaw
cycle. Twelve-lead electrocardiograms were recorded using a
Siemens Sicard 460 unit (Siemens AG, Erlangen, Ger-
many) and were analyzed and coded in accordance with
Minnesota Coding definitions at the University of Glasgow
Electrocardiography core laboratory based at the Glasgow
Royal Infirmary (24). The men were asked whether a doctor
had ever told them that they had angina or had experienced
a myocardial infarction (heart attack, coronary thrombosis),
HF, or stroke; details of their medications were recorded at
the examination. A total of 4,252 men (77% of survivors)
attended for examination. Of these men, we excluded 130
men with prevalent doctor-diagnosed HF and 18 men with
missing BMI data. We further excluded 24 men with a BMI
18.5 because these underweight men are likely to have
disease causing weight loss (25), leaving 4,080 men for
analysis.
Cardiovascular risk factors. Details of measurement and
classification methods for smoking status, physical activity,
social class, alcohol intake, blood pressure, blood lipids, sand measures of lung function
(forced expiratory volume in the
first second of expiration [FEV1]
values in this cohort were previ-
ously described [26,27]). Insulin
resistance was estimated according
to HOMA (homeostasis model
assessment)—the product of fast-
ing glucose (mmol/l) and insulin
(U/ml) divided by the constant
22.5 (28). Prevalent diabetes in-
cluded men with a diagnosis of
diabetes or men with fasting blood
glucose 7 mmol/l. C-reactive
protein (CRP) was assayed by
ultrasensitive nephelometry (Dade Behring, Milton Keynes,
United Kingdom). Men with pre-existing CHD included
those with a history of diagnosed myocardial infarction or
angina. Electrocardiographic left ventricular hypertrophy
was defined according to the Minnesota code (codes 3.1 or
3.3). Atrial fibrillation was defined according to Minnesota
codes 8.3.1 and 8.3.3.
Anthropometric measurements. Measurements included
height, weight, waist circumference (WC), and hip circum-
ference. Subjects were measured standing in light clothing
without shoes. Height was measured with a Holtain stadi-
ometer (Crosswell, United Kingdom) to the last complete
0.1 cm and weight with a Soehnle digital electronic scale
(Waagen, Murrhardt, Germany) to the last complete 0.1 kg.
BMI (weight/height2 in kg/m2) was calculated for each
ubject. WC was measured in duplicate with an insertion
ape (CMS Ltd., London, United Kingdom) at the mid-
oint between the iliac crest and the lower rib margins
easured in the midaxillary line.
eptin. Plasma leptin was measured by an in-house radio-
mmunoassay validated against the commercially available
inco assay, as previously described (26). The intra- and
nterassay coefficients of variation were 7% and 10%,
espectively, over the sample concentration range. The
etection limit of the assay was 0.5 ng/ml. There was no
ignificant diurnal variation in leptin concentration. Mean
eptin level in men screened before 1:00 PM was 9.4
interquartile range: 6.0 to 14.6) compared with 9.1 (inter-
uartile range: 5.6 to 14.4) in men screened after 1:00 PM.
ollow-up. All men have been followed from the initial
xamination (1978 to 1980) for cardiovascular morbidity,
nd follow-up has been achieved for 99% of the cohort (29).
n the present analyses, all-cause mortality and morbidity
vents are based on follow-up from rescreening in 1998 to
000 at mean age 60 to 79 years to July 2008, a mean
ollow-up period of 9 years (range 8 to 10 years). Informa-
ion on death was collected through the established “tag-
ing” procedures provided by the National Health Service
egisters. Fatal CHD events were defined as death with
HD (International Classification of Diseases-9th Revi-
Abbreviations
and Acronyms
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
CRP  C-reactive protein
FEV1  forced expiratory
volume in the first second
of expiration
HF  heart failure
HR  hazard ratio
WC  waist circumferenceion, codes 410 through 414) as the underlying code. A
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Obesity, Leptin, and Heart Failure October 25, 2011:1870–7nonfatal myocardial infarction was diagnosed according to
World Health Organization criteria (30). Evidence of
nonfatal myocardial infarction and HF was obtained by ad
hoc reports from general practitioners supplemented by
biennial reviews of the patients’ practice records (including
hospital and clinic correspondence) through to the end of
the study period Incident HF was based on a doctor-
confirmed diagnosis of HF from primary care records.
Statistical methods. The distribution of plasma leptin was
skewed, and log transformation was used. Chi-square tests
and t tests were used to compare the baseline characteristics
n Table 1. A Cox proportional hazards model was used to
ssess the multivariate-adjusted hazard ratio (HR) (relative
isk) in a comparison of tertiles of plasma leptin and for a
-SD increase in log leptin. In multivariate analyses, smok-
ng (never, long-term ex-smokers [15 years], recent ex-
mokers [15 years], and current smokers), social class
manual workers vs. nonmanual workers), physical activity
4 groups), alcohol intake (5 groups), diabetes (yes/no), use
f antihypertensive treatment (yes/no), use of statins (yes/
o), left ventricular hypertrophy (yes/no), and atrial fibril-
ation (yes/no) were fitted as categorical variables. Systolic
lood pressure, FEV1, and CRP were fitted continuously.
o assess the association between BMI and HF, we
onsidered BMI as both a continuous variable (per SD and
nit increase) and a categorical variable based on World
ealth Organization cutoffs (normal weight, 18.5 to 24.9
Baseline Characteristics (1998 to 2000) in 4,080 MenWith and Without Pre-Existing CHD According to Incident HF StatuTable 1 B seline Characteristics (1998 to 2 00) in 4,080 MeWith and Without Pre-Existing CHD According to Incid
No Pre-Existing CHD
No HF Incident HF
No. of men 3,212 148
Age, yrs 68.3 (5.4) 70.8 (5.2)
BMI 26.83 (3.5) 27.71 (3.8)
WC 97.0 (10.2) 99.6 (11.4)
Smokers 12.8 16.2
Inactive 31.4 42.4
Manual labor 52.5 57.4
Moderate/heavy drinkers 12.9 11.5
Diabetes 10.5 14.9
Stroke 3.9 8.4
LVH 7.2 12.2
AF 2.6 14.2
BP lowering therapy 19.5 35.8
Statins 2.6 2.0
Beta-blockers 8.7 18.2
SBP, mm Hg 150.2 (23.8) 156.2 (25.7)
DBP, mm Hg 86.0 (11.0) 86.9 (10.7)
Cholesterol, mmol/l 6.09 (1.06) 5.93 (1.08)
HDL-C, mmol/l 1.34 (0.34) 1.31 (0.37)
FEV1, l 2.64 (0.65) 2.35 (0.70)
CRP, mg/l 1.62 (0.8–3.2) 2.51 (1.2–4.3)
Leptin, ng/ml 8.94 (5.6–3.2) 11.59 (7.2–18.2)
Values are mean (SD), %, or geometric mean (interquartile range). p value: test for difference bet
AF  atrial fibrillation; BMI  body mass index; BP  blood pressure; CHD  coronary heart disease; C
rst second of expiration; HDL-C  high-density lipoprotein cholesterol; HF  heart failure; LVH  left veg/m2; overweight, 25.0 to 29.9 kg/m2; and obese, BMI
30 kg/m2). Similarly, we considered WC as both a
continuous variable and a categorical variable using 3
categories: 94 cm, 94 to 101 cm, and 102 cm (27). To
valuate whether leptin predicted HF independent of inci-
ent CHD during follow-up, we adjusted for incident
HD by fitting CHD as a time-dependent covariate.
esults
uring the mean follow-up period of 9 years, there were
28 incident HF cases (rate, 7.0/1,000 person-years) in the
,080 men with no diagnosed HF. Men with pre-existing
HD (n  720; 80 cases) had significantly higher rates of
F than men without CHD (n  3,360; 148 cases) (15.2
s. 5.4/1,000 person-years; p  0.0001). Men with pre-
xisting CHD had significantly higher mean plasma leptin
evels than men without (geometric mean 10.7 vs. 9.0; p 
.0001). Plasma leptin was equally and highly correlated
positively) with BMI and WC in both men with (r 0.54)
nd without (r  0.57) pre-existing CHD.
aseline characteristics. In both men with and without
re-existing CHD, those in whom HF developed were
ignificantly older and had significantly higher mean BMI
nd WC and lower FEV1 (Table 1). In men without CHD,
those in whom HF developed were less active and had
higher rates of stroke, diabetes, atrial fibrillation, antihyper-
F Status
With Pre-Existing CHD
p Value No HF Incident HF p Value
640 80
0.0001 69.6 (5.4) 71.1 (5.7) 0.02
0.0001 27.31 (3.9) 28.27 (4.3) 0.0001
0.0001 98.1 (10.3) 100.9 (11.3) 0.0001
0.22 11.6 7.5 0.28
0.006 43.0 42.7 0.96
0.24 56.3 61.1 0.39
0.62 10.5 10.0 0.90
0.09 12.3 17.5 0.19
0.003 9.7 12.5 0.43
0.02 8.0 12.5 0.17
0.0001 4.4 6.3 0.45
0.0001 34.5 31.9 0.67
0.67 28.6 23.8 0.36
0.0001 35.3 20.0 0.006
0.003 144.6 (24.3) 145.8 (24.7) 0.67
0.34 82.3 81.2 0.40
0.10 5.69 (1.07) 5.83 (1.12) 0.27
0.33 1.26 (0.32) 1.27 (0.28) 0.71
0.0001 2.51 (0.61) 2.33 (0.60) 0.01
0.0001 1.97 (1.0–4.1) 2.51 (0.8–5.4) 0.08
0.0001 10.49 (6.6–17.0) 12.18 (7.1–20.9) 0.13
o HF and incident HF.sn
ent H









ween n
RP  C-reactive protein; DBP  diastolic blood pressure; FEV1  forced expiratory volume in the
ntricular hypertrophy; SBP  systolic blood pressure; WC  waist circumference.
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October 25, 2011:1870–7 Obesity, Leptin, and Heart Failuretensive treatment, and beta-blocker use, and higher mean
systolic blood pressure and CRP. Plasma leptin levels were
significantly higher in those without CHD in whom HF
developed but not in men with CHD in whom HF
developed.
Plasma leptin and incident HF. Figure 1 shows the
Kaplan-Meier estimates of the cumulative incidence of HF
by tertiles of leptin in men with and without CHD and HF.
In men without CHD, high leptin (top third) was associ-
ated with a 2-fold increase in risk of incident HF compared
Figure 1 Kaplan-Meier Curves
Cumulative heart failure incidence by tertiles of leptin in men with and without prewith those in the lowest third, even after adjustment for age,smoking, physical activity, social class, antihypertensive
treatment, statin use, prevalent diabetes, prevalent stroke,
left ventricular hypertrophy, atrial fibrillation, use of beta-
blockers, FEV1, and BMI or WC (Table 2). However,
adding leptin to model 1 showed only slight improvement in
the c-statistics (0.726 [95% confidence interval (CI): 0.681
to 0.772] vs. 0.736 [95% CI: 0.694 to 0.779]; p  0.14 for
improvement]. The increased risk associated with increased
leptin remained significantly increased after further adjust-
ment for CRP. Leptin was not related to incident major
g coronary heart disease (CHD) and with no prevalent heart failure.-existinCHD events (age-adjusted HR tertile 3 vs. tertile 1: 1.01
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Obesity, Leptin, and Heart Failure October 25, 2011:1870–7[95% CI: 0.73 to 1.38]) and further adjustment for incident
CHD made no difference to the findings. Additional
adjustment for HOMA-insulin resistance, which correlated
highly with leptin (r  0.47), made little difference in the
ssociation between leptin and incident HF and the trend
ith increasing log leptin remained significant (p 0.02 for
rend) (adjusted HR tertile 3 vs. tertile 1: 1.90 [95% CI:
.10 to 3.29]; p  0.02). In men with pre-existing CHD,
eptin showed a weak positive association with incident HF
p  0.07 for increase in log leptin; model 1), and this was
ompletely abolished after adjustment for BMI.
MI, WC, and incident HF. In men without pre-existing
HD, obesity was associated with a greater than 2-fold
ncrease in risk of HF after adjustment for age (Table 3).
urther adjustment for a wide range of potential confound-
rs and mediators shown to be associated with HF in Table
(Table 3, model 1) attenuated the increased risk associated
ith increased BMI, but the association remained signifi-
ant (p  0.02 for trend). Additional adjustment for CRP
(model 2) reduced the association further, but the trend
remained marginally significant (p  0.05). However,
further adjustment for plasma leptin (model 3) abolished the
association between BMI and incident HF. Similar patterns
of association were seen for WC, although the association
was somewhat weaker than that seen for BMI. In men with
pre-existing CHD, increasing BMI was associated with a
significant increase in the risk of HF, which remained
significant after adjustment for leptin (p  0.03). WC
showed similar patterns of association with BMI. Adjust-
ment for incident CHD made little difference to these
findings.
Discussion
In this study of older men, increased BMI (and to a lesser
extent WC) is associated with a significant increase in the
risk of HF in both men with and without pre-existing
CHD. Our findings are consistent with those of other
prospective studies in middle-aged and elderly populations
(2–12) and extend the findings further by examining the
Plasma Leptin Concentration and Adjusted HR (95% CI) for IncidenTable 2 Plasma Leptin Concentration and Adjusted HR (95% C
No CHD
Leptin, ng/ml
T3 vs. T1
p Value
T3 vs. T1
HR for 1-SD
Increase in
Log Leptin
Age adjusted 2.39 (1.55–3.66) 0.0001 1.40 (1.18–1.66)
Model 1 2.15 (1.36–3.38) 0.001 1.34 (1.13–1.59)
Model 1  BMI only 2.08 (1.24–3.49) 0.006 1.32 (1.09–1.61)
Model 1  WC only 2.28 (1.35–3.86) 0.002 1.37 (1.13–1.67)
Model 2 1.98 (1.18–3.34) 0.01 1.30 (1.06–1.60)
Model 3 1.98 (1.17, 3.34) 0.01 1.30 (1.06–1.61)
p value for trend is the test for 1-SD increase based on continuous log-transformed values. Model 1 i
prevalent stroke, left ventricular hypertrophy, atrial fibrillation, use of beta-blockers, and forced exp
3 is model 2  incident CHD.
CI  confidence interval; HR  hazard ratio; T1  tertile 1; T3  tertile 3; other abbreviationscontributing role of plasma leptin to the obesity-HF rela- itionship. In those without CHD, plasma leptin appears to
be a potential link between obesity and increased HF; in
men with CHD, the association between BMI and HF was
independent of plasma leptin concentrations. CHD is a
major cause of HF; in men with pre-existing CHD, obesity
may have an added effect on increasing the cardiac workload
triggering HF.
Although obesity (BMI30 kg/m2) is well established as
eing associated with a significantly increased risk of HF,
he risk associated with being overweight has been less
learly defined. Our findings of a significant increase in the
isk of HF associated with obesity and a trend toward
ncreasing risk even in the overweight group are consistent
ith those of other studies (2,4,5) and supports the possi-
ility that both overweight and obesity are associated with
ncreased risk of HF (4). We found both BMI and WC to
e associated with HF, as reported in other studies
3,5,7,11,12) and that BMI appeared to be at least as strong
predictor of HF as WC. This and other findings do not
upport the suggestion that WC is a better predictor of HF
han BMI (9). Other recent data also suggest that BMI and
C are broadly equivalent in their prediction of CHD
vents in men (31). In the present study, it is not possible to
isentangle the independent effects of BMI and WC as the
measures are so highly correlated in these men (r  0.86).
The pathways by which obesity plays a role in HF are not
et fully understood but may have both indirect effects via
stablished risk factors such as hypertension and diabetes
nd a direct effect on the heart tissues and muscle itself (32).
he relationship between obesity and HF has been shown
o be independent of established risk factors including
iabetes, CHD, and hypertension (2–14). Several mecha-
isms have been proposed to explain the association of
besity and HF including inflammatory pathways and
bnormalities in adipokine pathways (15,16). Adipose tissue
s a major source of proinflammatory cytokines, which has
een associated with incident HF (33). Although the
ESA (Multi-Ethnic Study of Atherosclerosis) found the
ssociation between BMI and HF to be dependent on
in Men With and Without Pre-Existing CHDIncident HF in Men With and Without Pre-Existing CHD
With CHD
Value
Trend
Leptin, ng/ml
T3 vs. T1
p Value
T3 vs. T1
HR for 1-SD
Increase in
Log Leptin
p Value
for Trend
.0001 1.39 (0.79, 2.44) 0.25 1.25 (1.00–1.56) 0.06
.0008 1.36 (0.75–2.50) 0.31 1.26 (0.98–1.60) 0.07
.006 0.88 (0.44–1.76) 0.71 1.07 (0.79–1.44) 0.67
.002 0.94 (0.47–1.89) 0.86 1.10 (0.82–1.49) 0.51
.01 0.77 (0.37–1.57) 0.77 1.01 (0.74–1.38) 0.94
.01 0.85 (0.41–1.78) 0.67 1.06 (0.77–1.45) 0.72
ted for age, smoking, physical activity, social class, antihypertensive treatment, prevalent diabetes,
olume in the first second of expiration. Model 2 is model 1 BMI C-reactive protein, and model
ble 1.t HFI) for
p
for
0
0
0
0
0
0
s adjus
iratory vnflammatory markers (15), others have shown adiposity
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factor-alpha) (9). We have shown the association between
obesity and HF to be independent of CRP in both men
with and without CHD.
Leptin has been proposed as a potential link between
obesity and HF (17,18), but few studies have examined this
hypothesis. Clinical and animal models suggest a putative
role for leptin in cardiac and vascular remodeling; however,
the independent (of BMI) association between leptin and
CHD is weak (34), and the association with the risk of HF
has not been well studied. Only 1 study (the Framingham
study) examined the prospective association between leptin
and incident HF, and the association was found to be
dependent on BMI in their elderly population (22). We
have observed that in those without CHD, leptin was
positively associated with an increased risk of HF indepen-
dent of BMI and inflammation and HOMA–insulin resis-
tance. The nonsignificant findings in the Framingham study
may be due to the inclusion of those with pre-existing
CHD, which is highly prevalent in the elderly whereby
HR (95% CI) for Incident HF Associated With BMI and WC in MenTable 3 HR (95% CI) for Incident HF Associated With BMI and
n Rates (n) Age Adju
Men without CHD
BMI, kg/m2
25 1,040 3.9 (33) 1.00
25–29.9 1,784 5.6 (82) 1.52 (1.02
30 536 7.5 (32) 2.17 (1.33
Unit increase in BMI 1.08 (1.03
1-SD difference in BMI 1.31 (1.14
p value for trend 0.000
WC, cm
94 1,291 4.2 (45) 1.00
94–101 1,112 5.9 (53) 1.42 (0.95
102 945 6.4 (49) 1.58 (1.06
Unit increase in WC 1.03 (1.01
1-SD difference in WC 1.32 (1.12
p value for trend 0.000
Men with CHD
BMI, kg/m2
25 194 12.4 (17) 1.00
25–29.9 364 15.0 (40) 1.26 (0.72
30 162 19.3 (23) 1.76 (0.94
Unit increase in BMI 1.07 (1.01
1-SD difference in BMI 1.30 (1.06
p value for trend 0.01
WC, cm
94 238 12.9 (23) 1.00
94–101 234 12.3 (21) 0.95 (0.53
102 241 20.6 (36) 1.73 (1.03
Unit increase in WC 1.03 (1.01
1-SD difference in WC 1.31 (1.07
p value for trend 0.01
1-SD difference HR per 1-SD. p value for trend is the test for unit increase in BMI and WC based o
reatment, prevalent diabetes, prevalent stroke, left ventricular hypertrophy, atrial fibrillation, use
C-reactive protein, and model 3 is model 1  leptin.
Abbreviations as in Tables 1 and 2.leptin was not seen to be associated with HF, thus dilutingany potential adverse association of increased leptin with
HF. Alternatively, the difference in findings may potentially
be due to the inclusion of women in the Framingham study.
Leptin levels vary by sex (22), and it is possible that there are
interactions between sex, leptin, and incident HF that we
were not able to explore in this study of men only.
Interestingly, leptin was not shown to be related to
incident CHD in this study. This is consistent with findings
in an earlier phase of the present study and with findings of
several other prospective studies (34), but leptin was
strongly related to incident HF. Leptin is secreted by
adipose cells; in those without CHD, obesity-induced
hyperleptinemia may injure peripheral tissues including
vasculature and myocardium (21). Although experimental
evidence suggests that leptin may contribute to cardiac
hypertrophy and induce mitogenesis in primary cardio-
myocytes (17,20,21) leading to HF (35), it is also possible
that leptin is a marker of other pathways by which obesity
may influence HF. Leptin appears to have numerous met-
abolic and vascular effects, both favorable and potentially
and Without Pre-Existing CHDin Men With and Without Pre-Existing CHD
Model 1 Model 2 Model 3
1.00 1.00 1.00
1.45 (0.95–2.19) 1.37 (0.90–2.10) 1.11 (0.56–1.85)
1.63 (0.98–2.71) 1.45 (0.86–2.45) 1.01 (0.56–1.83)
1.05 (1.01–1.10) 1.05 (1.01–1.10) 1.00(0.95–1.07)
1.19 (1.04–1.37) 1.18 (1.00–1.39) 1.02 (0.83–1.25)
0.03 0.05 0.85
1.00 1.00 1.00
1.31 (0.87–1.97) 1.25 (0.83–1.88) 0.97 (0.63–1.51)
1.20 (0.74–1.84) 1.12 (0.73–1.72) 0.82 (0.51–1.34)
1.02 (0.99–1.03) 1.01 (0.99–1.03) 0.99 (0.98–1.02)
1.17 (0.99–1.37) 1.14 (0.95–1.37) 0.98 (0.80–1.20)
0.08 0.14 0.86
1.00 1.00 1.00
1.26 (0.71–2.25) 1.15 (0.64–2.08) 1.02 (0.55–1.91)
1.89 (0.96–3.70) 2.05 (1.04–4.06) 1.62 (0.73–3.68)
1.07 (1.01–1.14) 1.09 (1.03–1.16) 1.09 (1.01–1.18)
1.32 (1.04–1.66) 1.37 (1.09–1.72) 1.42 (1.05–1.94)
0.02 0.006 0.03
1.00 1.00 1.00
0.87 (0.47–1.61) 0.95 (0.51–1.76) 0.80 (0.42–1.54)
1.68 (0.97–2.91) 1.81 (1.03–3.21) 1.59 (0.80–3.17)
1.03 (1.00–1.05) 1.03 (1.00–1.05) 1.02 (0.99–1.05)
1.30 (1.06–1.59) 1.31 (1.07–1.61) 1.26 (0.9–1.71)
0.02 0.02 0.13
uous values. Model 1 is adjusted for age, smoking, physical activity, social class, antihypertensive
a-blockers, and forced expiratory volume in the first second of expiration. Model 2 is model 1 WithC
sted
–2.28)
–3.53)
–1.12)
–1.50)
4
–2.11)
–2.38)
–1.04)
–1.55)
7
–2.23)
–3.31)
–1.13)
–1.60)
–1.73)
–2.44)
–1.05)
–1.61)
n contin
of betunfavorable (26). However, leptin (which reflects the per-
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1 of a range of active adipocytokines released by adipose
tissues. Therefore, one cannot exclude other substances
released from adipose tissue or even other factors determin-
ing fat mass accumulation as being relevant to the develop-
ment of HF in obese men without CHD. Further studies
are needed to determine the pathways.
By contrast, in those with pre-existing CHD, no signif-
icant association was seen between leptin and HF, even
before adjustment for BMI. This may reflect the much
higher risk of HF in those with established heart disease, so
that leptin has no discernible additional effect in those with
already damaged myocardium. Alternatively, it is possible
that the increased levels of leptin that occur after a myocar-
dial infarction (36) (consistent with the higher levels of
leptin observed in those with pre-existing CHD in the
present study) have different vascular associations compared
with leptin levels in men without CHD (37). The findings,
that the association of BMI and HF appears largely inde-
pendent of leptin in those with pre-existing CHD, are
consistent with recent reports from the Heart and Soul
Study (13). This study shows obesity to be associated with
hospitalization with HF independent of leptin and CRP
and suggests that other mechanisms are likely to be impor-
tant. Obesity is linked to increased blood volume in the
body, increased cardiac workload, diastolic dysfunction, and
hypertrophy, which can lead to HF in those with pre-
existing CHD (32,38).
Study limitations. The current findings are based on
doctor-diagnosed HF, which is likely to underestimate the
true incidence of HF in this study population. Moreover,
because the current study was based primarily on men of
white European origin, further studies are needed in women
and in other ethnic groups.
Conclusions
Our data suggest that the association between obesity and
HF may in part be mediated by leptin in those with no
pre-existing CHD. In those with CHD, the association
between BMI and HF appears to be independent of leptin.
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